Once-daily inhaled corticosteroids in children with asthma: Dry powder inhalers

Drugs

Volumn 58, Issue SUPPL. 4, 1999, Pages 35-41

  Möller, Christian ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; PREDNISOLONE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHILD; CLINICAL TRIAL; COLLAGEN METABOLISM; DISEASE CONTROL; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INHIBITION; DRY POWDER; HUMAN; LONG TERM CARE; LUNG FUNCTION; MEDICAL NEBULIZER; METERED DOSE INHALER; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW;

EID: 0343293814     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958004-00005     Document Type: Review

References (73)

1. International Consensus Report on Diagnosis and Management of Asthma. International Asthma Management Project. Allergy 1992; 47 Suppl. 13: 1-61
2. Anon. Asthma: a follow up statement from an international paediatric asthma consensus group. Arch Dis Child 1992; 67: 240-8
3. Global Initiative for Asthma. NHLBI/WHO Workshop report. NIH Publication 95-3659. Bethesda: National Heart, Lung and Blood Institute, National Institutes of Health, 1995
4. Dahl R, Bjermer L, editors. Nordic consensus report on asthma management. Respir Med 1999; 93
5. Bousquet J, Lockey RF, Mailing H-J, editors. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 Suppl. 44: 1-42
6. Nakamura Y, Hoshino M, Sim JJ, et al. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53: 835-41
7. Palmqvist M, Balder B, Lowhagen O, et al. Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist. J Allergy Clin Immunol 1992; 89: 844-9
8. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998; 102: 531-8
9. Simons FE. Benefits and risks of inhaled glucocorticoids in children with persistent asthma. J Allergy Clin Immunol 1998; 102: S77-84
10. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-81
11. van Essen-Zandvliet EE, Dutch Chronic Nonspecific Lung Disease Study Group. Long-term intervention in childhood asthma: the Dutch study results. Mon Arch Chest Dis 1995; 50: 201-7
12. Hussar DA. Patient non-compliance. J Am Pharm Assoc 1975; 15: 183-201
13. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7
14. Mann M, Eliasson O, Patel K, et al. A comparison of effects of bid and qid dosing on compliance with inhaled flunisolide. Chest 1992; 101: 496-9
15. Matthew D, Hingson R. Improving patient compliance: a guide for physicians. Med Clin North Am 1971; 61: 879-89
16. McAllisler WA, Hetzel M, Emery P, et al. Comparison of efficacy and adrenal suppression produced by alternate-day, daily and twice-daily prednisolone regimens for chronic asthma. Thorax 1983; 38: 230-1
17. Toogood J, Jennings B, Lefcoe N. Morning-dose beclomethasone aerosol (BA) is clinically effective and spares adrenal function. Ann R Coll Phys Surg (Can) 1980; 13: 110
18. Toogood JH, Baskerville JC, Jennings B, et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid budesonide. J Allergy Clin Immunol 1982; 70: 288-98
19. Byron MA, Jackson J, Ansell BM. Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis. J R Soc Med 1983; 76: 452-7
20. Casaneuva FF, Burguera B, Tome MA. Depending on the time of administration, dexamethasone potentiates or blocks growth hormone release in man. Neuroendocrinology 1990; 51: 46-91
21. Heuck C, Wolthers OD, Kollerup G, et al. Adverse effects of inhaled budesonide (800μg) on growth and collagen tunover in children with asthma: a double-blind comparison of once-daily versus twice-daily administration. J Pediatr 1998; 133: 608-12
22. Dahl R, Johansson SA. Clinical effect of b.i.d. and q.i.d. administration of inhaled budesonide, a double-blind controlled study. Eur J Respir Dis 1982; 63 Suppl. 122: 268-9
23. Toogood JH. Concentrated aerosol formulations in asthma. Lancet 1983; 2: 790-1
24. Malo JL, Ghezzo H, Trudeau C, et al. Duration of action of inhaled terbutaline at two different doses and of albuterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in asthmatic subjects. Am Rev Respir Dis 1989; 140: 817-21
25. Malo J-L, Cartier A, Ghezzo H, et al. Comparison of four-times-a-day and twice-a-day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma. Respir Med 1995; 89: 537-43
26. Mecoy R, Laby B. Beclomethasone dipropionate in twice daily treatment of asthma. Aust Fam Physician 1980; 9: 721-8
27. Munch EP, Taudorf E, Weeke B. Dose frequency in the treatment of asthmatics with inhaled topical steroids. Eur J Respir Dis 1982; 63: 143
28. Nyholm E, Frame MH, Cayton RM. Therapeutic advantage of twice-daily over four-times-daily inhalation budesonide in the treatment of chronic asthma. Bur J Respir Dis 1984; 65: 339-45
29. Meltzer EO, Kemp JP, Welch MJ, et al. Effect of dosing schedule on efficacy of beclomethasone dipropionate aerosol in chronic asthma. Am Rev Respir Dis 1985; 131: 732-6
30. Boyd G, Abdallah S, Clark R. Twice or four times daily beclomethasone dipropionate in mild stable asthma? Clin Allergy 1985; 15: 383-9
31. So SY, Lam WK. Twice daily administration of beclomethasone dipropionate dry-powder in the management of chronic asthma. Asian Pac J Allergy Immunol 1986; 4: 129-32
32. Williams H, Jones ER, Silbert JR. Twice daily versus four times daily treatment with beclomethasone dipropionate in the control of mild childhood asthma. Thorax 1986; 41: 602-5
33. Smith MJ, Hodson ME. Twice daily beclomethasone dipropionale administered w ith a concentrated aerosol inhaler: efficacy and patient compliance. Thorax 1986; 41: 960-3
34. Tukiainen H, Vaara J, Terho E, et al. Comparison of twice-daily and four-times daily administration of beclomethasone dipropionate in patients with severe chronic bronchial asthma. Eur J Clin Pharmacol 1986; 30: 319-22
35. Reinberg A, Halberg F, Falliers CJ. Circadian timing of methylprednisolone effects in asthmatic boys. Chronobiologia 1974; 1: 333-47
36. Pincus DJ, Szefler SJ, Ackerson LM, et al. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1995; 95: 1172-8
37. Gagnon M, Cote J, Milot J, et al. Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma. Chest 1994; 105: 1732-7
38. McGivern DV, Ward M, Macfarlane JT, et al. Failure of once daily inhaled corticosteroid treatment to control chronic asthma. Thorax 1984; 39: 933-4
39. Stiksa G, Glennow C. Once daily inhalation of budesonide in the treatment of chronic asthma: a clinical comparison. Ann Allergy 1985; 55: 49-51
40. Munch EP, Laursen LC, Dirksen A, et al. Dose frequency in the treatment of asthmatics with inhaled topical steroids. Comparison between a twice daily and a once daily dosing regimen. Eur J Respir Dis 1985; 67: 254-60
41. Jones AH, Langdon CG, Lee PS, et al. Pulmicort Turbuhaler once daily as initial prophylactic therapy for asthma. Respir Med 1994; 88: 293-9
42. Campbell LM, Gunn SD, Sweeney D, et al. Once daily budesonide: effective control of moderately severe asthma with 800 μg once daily inhaled via Turbuhaler when compared with 400 μg twice daily. Eur J Clin Res 1995; 7: 1-14
43. Weiner P, Weiner M, Azgad Y. Long-term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma. Thorax 1995; 50/12: 1270-3
44. ZuWallack RL, Roscn JP, Cohen L, et al. The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. J Allergy Clin Immunol 1997; 99: 278-85
45. Chisholm SL, Dekker FW, Knuistingh Neven A, et al. Once-daily budesonide in mild asthma. Respir Med 1998; 92: 421-5
46. Venables TL, Addlestone MB, Smithers AJ, et al. A comparison of the efficacy and patient acceptability of once daily budesonide via Turbuhaler and twice daily fluticasone propionate via Diskhaler at an equal daily dose of 400 mcg in adult asthmatics. Br J Clin Res 1996; 7: 15-32
47. Johansson L-O. A comparison of once-daily fluticasone propionate (FP) 200 μg and budesonide (bud) 400 μg and twice-daily of fluticasone propionate (FP) 100 μg [abstract]. Am J Resp Crit Care Med 1998; 157 (3 Pt 2): A404
48. Miller-Larsson A, Mattson H, Ohlsson D, et al. Prolonged release from the airways tissue of glucocorticoids BUD and fluticasone dipropionate as compared to beclomethasone dipropionate and hydrocortisone. Am J Respir Crit Care Med 1994; 149 (4 Pt 2): A466
49. Brattsand R, Miller-Larsson A, Wieslander E, et al. Reversible fatty acid conjugation of budesonide - a mechanism contributing to prolonged local retention and activity. Eur Respir J 1997; 10 Suppl. 25: 296S
50. Miller-Larsson A, Jansson P, Runström A, et al. Reversible fatty acid conjugation of budesonide results in a prolonged topical anti-inflammatory activity in airways as compared to fluticasone propionate. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A353
51. Miller-Larsson A, Hjertberg E, Mattson H, et al. Reversible fatty acid conjugation of budesonide results in a prolonged retention in airway tissue as compared to fluticasone propionate. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A353
52. Wieslander E, Delander EL, Järkelid L, et al. Reversible fatty acid conjugation of budesonide results in prolonged anti-inflammatory activity as compared to fluticasone propionate. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A353
53. Agertoft L, Pedersen S. Importance of training for correct Turbuhaler use in preschool children. Acta Paediatr 1998; 87: 842-7
54. de Blic J, Delacourt C, Le Bourgeois M, et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol 1996; 98: 14-20
55. Ilangovan P, Pedersen S, Godfrey S, et al. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993; 68: 356-9
56. Bingham A, Manjra AL, Lee BW, et al. A comparison of the effect of nebulised fluticasone propionate Img twice daily with oral prednisolone in children aged 4-16 years with an acute exacerbation of asthma. Am J Respir Crit Care Med 1998; 157 (3): A404
57. Francis P, Geelhoed G, Harris MA, et al. Effect of nebulised fluticasone propionate 1mg twice daily compared with oral prednisolone in pre-sehool children aged 48 months or less with an acme exacerbation of asthma. Eur Respir J 1997; 10 Suppl. 25: 275S
58. Webb MS, Milner AD, Hiller EJ, et al. Nebulised beclomethasone dipropionate suspension. Arch Dis Child 1986; 61 (11): 1108-10
59. Agertoft L, Andersen A, Weibull E, et al. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child 1999; 80 (3): 241-7
60. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65: 308-19
61. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler (P-MDI). Eur Respir J 1994; 7: 1839-44
62. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69 (1): 130-3
63. Pauwels RA, Hargreave FE, Camus P, et al. A 1-year comparison of Turbuhaler vs pressurized metered-dose inhaler in asthmatic patients. Chest 1996; 110: 53-7
64. Schlaeppi M, Edwards K, Fuller RW, et al. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Pract 1996; 50 (1): 14-9
65. Bisgaard H, Klug B, Sumby BS, et al. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998; 11 (5): 1111-5
66. Lipworth BJ, Clark DJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulmon Pharmacol Ther 1997; 10 (4): 211-4
67. Wildhaber JH, Devadason SG, Wilson JM, et al. Lung deposition of budesonide from Turbuhaler in asthmatic children. Eur J Pediatr 1998; 157 (12): 1017-22
68. Bisgaard H, Pedersen S, Nikander K. Use of budesonide Turbuhaler in young children suspected of asthma. Eur Respir J 1994; 7: 740-2
69. McCarthy TP. The use of a once daily inhaled glucocorticosteroid (budesonide) in the management of childhood asthma. Br J Clin Res 1993; 4: 55-61
70. Campbell LM, Bodalia B, Gogbashian CA, PETITE Research Group, et al. Once-daily budesonide: 400 micrograms once daily is as effective as 200 micrograms twice daily in controlling childhood asthma. Int J Clin Practice 1998; 52: 213-9
71. Jónasson G, Carlsen KH, Blomqvist P. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated w ith steroids. Eur Respir J 1998; 12: 1099-104
72. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992; 146: 547-54
73. Möller C, Strömberg L, Oldacus G, et al. Efficacy of once-daily versus twice-daily administration of budesonide via Turbuhaler in children with stable asthma. Pediatr Pulmonol. In press